Henan Taloph Pharmaceutical Stock Co.,Ltd (SHA:600222)

SHA:600222 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	1,772	1,936	2,065	1,945	1,602	1,416
Other Revenue	4.39	5.2	4.95	15.33	2.83	1.4
Revenue	1,777	1,941	2,070	1,961	1,605	1,417
Revenue Growth (YoY)	-11.31%	-6.21%	5.57%	22.20%	13.23%	8.03%
Cost of Revenue	1,350	1,441	1,508	1,492	1,148	1,046
Gross Profit	427.05	500.1	561.55	468.4	456.85	370.88
Selling, General & Admin	270.46	307.58	339.5	317.51	246.89	211.37
Research & Development	66.64	100.89	127.71	116.52	56.5	63.66
Other Operating Expenses	10.56	8.63	6.54	8.42	2.59	7.08
Operating Expenses	353.28	424.2	485.6	476.27	331.51	294.65
Operating Income	73.77	75.9	75.94	-7.87	125.34	76.23
Interest Expense	-58.09	-59.64	-54.37	-64.63	-83.84	-74.44
Interest & Investment Income	4.7	6.37	2.17	2.22	6.74	12.06
Other Non Operating Income (Expenses)	-0.97	-1.51	10.8	-1.56	-2.46	-3.44
EBT Excluding Unusual Items	19.42	21.12	34.54	-71.84	45.78	10.4
Gain (Loss) on Sale of Investments	8.29	7.94	-6.42	-11.87	-10.17	2.38
Gain (Loss) on Sale of Assets	-0.03	0.13	0.54	0.03	-1.57	0.2
Asset Writedown	-	-	-	-0.15	-29.9	-
Legal Settlements	-	-	-	-11.61	-1.62	-
Other Unusual Items	10	5.88	14.31	12.59	4.93	16.25
Pretax Income	37.67	35.07	42.96	-82.85	7.45	29.24
Income Tax Expense	-12.4	-18.42	-1.87	-7.09	0.67	1.64
Earnings From Continuing Operations	50.07	53.5	44.83	-75.76	6.78	27.6
Minority Interest in Earnings	-6.81	-2.97	-1.27	3.56	-0.78	1.65
Net Income	43.25	50.53	43.56	-72.2	6	29.24
Net Income to Common	43.25	50.53	43.56	-72.2	6	29.24
Net Income Growth	-60.14%	16.00%	-	-	-79.50%	-34.16%
Shares Outstanding (Basic)	554	556	563	562	560	547
Shares Outstanding (Diluted)	554	556	563	562	560	547
Shares Change (YoY)	-0.87%	-1.12%	0.07%	0.36%	2.52%	-1.68%
EPS (Basic)	0.08	0.09	0.08	-0.13	0.01	0.05
EPS (Diluted)	0.08	0.09	0.08	-0.13	0.01	0.05
EPS Growth	-59.79%	17.31%	-	-	-80.00%	-33.04%
Free Cash Flow	-95.85	-76.82	0.6	-191.03	60.58	0.77
Free Cash Flow Per Share	-0.17	-0.14	0.00	-0.34	0.11	0.00
Dividend Per Share	0.028	0.028	0.018	-	0.010	0.016
Dividend Growth	55.56%	55.56%	-	-	-37.50%	-
Gross Margin	24.04%	25.76%	27.13%	23.89%	28.47%	26.17%
Operating Margin	4.15%	3.91%	3.67%	-0.40%	7.81%	5.38%
Profit Margin	2.44%	2.60%	2.10%	-3.68%	0.37%	2.06%
Free Cash Flow Margin	-5.39%	-3.96%	0.03%	-9.74%	3.78%	0.06%
EBITDA	124.82	127.2	127.23	39.37	169.33	117.65
EBITDA Margin	7.03%	6.55%	6.15%	2.01%	10.55%	8.30%
D&A For EBITDA	51.06	51.3	51.29	47.24	43.99	41.42
EBIT	73.77	75.9	75.94	-7.87	125.34	76.23
EBIT Margin	4.15%	3.91%	3.67%	-0.40%	7.81%	5.38%
Effective Tax Rate	-	-	-	-	9.01%	5.62%
Revenue as Reported	1,777	1,941	2,070	1,961	1,605	1,417
Advertising Expenses	-	26.78	35.78	39.78	24.05	14.17

Source: S&P Global Market Intelligence. Standard template. Financial Sources.